» Articles » PMID: 33355857

The Association Between Mortality and the Oxygen Saturation and Fraction of Inhaled Oxygen in Patients Requiring Oxygen Therapy Due to COVID-19-Associated Pneumonia

Overview
Specialty Pulmonary Medicine
Date 2020 Dec 28
PMID 33355857
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The coronavirus disease (COVID-19) can manifest in a range of symptoms, including both asymptomatic systems which appear nearly non-existent to the patient, all the way to the development of acute respiratory distress syndrome (ARDS). Specifically, COVID-19-associated pneumonia develops into ARDS due to the rapid progression of hypoxia, and although arterial blood gas analysis can assist in halting this deterioration, the current environment provided by the COVID-19 pandemic, which has led to an overall lack of medical resources or equipment, has made it difficult to administer such tests in a widespread manner. As a result, this study was conducted in order to determine whether the levels of oxygen saturation (SpO2) and the fraction of inhaled oxygen (FiO2) (SF ratio) can also serve as predictors of ARDS and the patient's risk of mortality.

Methods: This was a retrospective cohort study conducted from February 2020 to Mary 2020, with the study's subjects consisting of COVID-19 pneumonia patients who had reached a state of deterioration that required the use of oxygen therapy. Of the 100 COVID-19 pneumonia cases, we compared 59 pneumonia patients who required oxygen therapy, divided into ARDS and non-ARDS pneumonia patients who required oxygen, and then investigated the different factors which affected their mortality.

Results: At the time of admission, the ratios of SpO2, FiO2, and SF for the ARDS group differed significantly from those of the non-ARDS pneumonia support group who required oxygen (p<0.001). With respect to the predicting of the occurrence of ARDS, the SF ratio on admission and the SF ratio at exacerbation had an area under the curve which measured to be around 85.7% and 88.8% (p<0.001). Multivariate Cox regression analysis identified that the SF ratio at exacerbation (hazard ratio [HR], 0.916; 95% confidence interval [CI], 0.846-0.991; p=0.029) and National Early Warning Score (NEWS) (HR, 1.277; 95% CI, 1.010-1.615; p=0.041) were significant predictors of mortality.

Conclusion: The SF ratio on admission and the SF ratio at exacerbation were strong predictors of the occurrence of ARDS, and the SF ratio at exacerbation and NEWS held a significant effect on mortality.

Citing Articles

Early pulmonary fibrosis-like changes between delta and pre-delta periods in patients with severe COVID-19 pneumonia on mechanical ventilation.

Yoo J, Kim W, Chung C, Cho Y, Lee J, Jegal Y Sci Rep. 2024; 14(1):26101.

PMID: 39478105 PMC: 11525473. DOI: 10.1038/s41598-024-77405-7.


Mortality Rate of COVID-19 With Comorbid Pneumonia in a Rural Area.

Multani A, Kollipara V, Krage T, Hearn J, Stahl G, Johnson K Cureus. 2024; 16(7):e63780.

PMID: 39099962 PMC: 11297188. DOI: 10.7759/cureus.63780.


SCARLET (Supplemental Citicoline Administration to Reduce Lung injury Efficacy Trial): study protocol for a single-site, double-blinded, placebo-controlled, and randomized Phase 1/2 trial of i.v. citicoline (CDP-choline) in hospitalized SARS....

Pannu S, Exline M, Bednash J, Englert J, Diaz P, Bartlett A Trials. 2024; 25(1):328.

PMID: 38760804 PMC: 11102211. DOI: 10.1186/s13063-024-08155-0.


Recent advances in cardiorespiratory monitoring in acute respiratory distress syndrome patients.

Chiumello D, Fioccola A J Intensive Care. 2024; 12(1):17.

PMID: 38706001 PMC: 11070081. DOI: 10.1186/s40560-024-00727-1.


A Simple Risk Formula for the Prediction of COVID-19 Hospital Mortality.

Plasek J, Dodulik J, Gai P, Hrstkova B, Skrha Jr J, Zlatohlavek L Infect Dis Rep. 2024; 16(1):105-115.

PMID: 38391586 PMC: 10887710. DOI: 10.3390/idr16010008.


References
1.
Bellani G, Laffey J, Pham T, Fan E, Brochard L, Esteban A . Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016; 315(8):788-800. DOI: 10.1001/jama.2016.0291. View

2.
Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L . COVID-19 pneumonia: different respiratory treatments for different phenotypes?. Intensive Care Med. 2020; 46(6):1099-1102. PMC: 7154064. DOI: 10.1007/s00134-020-06033-2. View

3.
Kangelaris K, Ware L, Wang C, Janz D, Zhuo H, Matthay M . Timing of Intubation and Clinical Outcomes in Adults With Acute Respiratory Distress Syndrome. Crit Care Med. 2015; 44(1):120-9. PMC: 4774861. DOI: 10.1097/CCM.0000000000001359. View

4.
Kashani K . Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes. Mayo Clin Proc. 2020; 95(6):1094-1096. PMC: 7177114. DOI: 10.1016/j.mayocp.2020.04.021. View

5.
Bilan N, Dastranji A, Ghalehgolab Behbahani A . Comparison of the spo2/fio2 ratio and the pao2/fio2 ratio in patients with acute lung injury or acute respiratory distress syndrome. J Cardiovasc Thorac Res. 2015; 7(1):28-31. PMC: 4378672. DOI: 10.15171/jcvtr.2014.06. View